Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma

Autor: Armands Sivins, Jin Park, Ji Qiu, Stacy Williams, Lusheng Song, Charles S. Rabkin, Weimin Gao, Yunro Chung, Marcis Leja, Minkyo Song, Joshua LaBaer, Jennifer Van Duine, Kailash Karthikeyan, Jolanta Lissowska, Kyoung-Mee Kim, M. Constanza Camargo, Jeffrey I. Cohen
Rok vydání: 2021
Předmět:
Zdroj: Gastric Cancer
ISSN: 1436-3305
1436-3291
Popis: BACKGROUND: Around 10% of gastric carcinomas (GC) contain Epstein-Barr virus (EBV) DNA. We characterized the GC-specific antibody response to this common infection, which may provide a noninvasive method to detect EBV-positive GC and elucidate its contribution to carcinogenesis. METHODS: Plasma samples from EBV-positive (n=28) and EBV-negative (n=34) Latvian GC patients were immune-profiled against 85 EBV proteins on a multi-microbial Nucleic Acid Programmable Protein Array (EBV-NAPPA). Antibody responses were normalized for each sample as ratios to the median signal intensity (MNI) across all antigens, with seropositivity defined as MNI ≥2. Antibodies with ≥20% sensitivity at 95% specificity for tumor EBV status were verified by enzyme-linked immunosorbent assay (ELISA) and validated in independent samples from Korea and Poland (n=24 EBV-positive, n=65 EBV-negative). RESULTS: Forty anti-EBV IgG and 8 IgA antibodies were detected by EBV-NAPPA in ≥10% of EBV-positive or EBV-negative GC patients, of which 9 IgG antibodies were discriminative for tumor EBV status. Eight of these nine were verified and seven were validated by ELISA: anti-LF2 (odds ratio=110.0), anti-BORF2 (54.2), anti-BALF2 (44.1), anti-BaRF1 (26.7), anti-BXLF1 (12.8), anti-BRLF1 (8.3), and anti-BLLF3 (5.4). The top three had areas under receiver operating characteristics curves of 0.81–0.85 for distinguishing tumor EBV status. CONCLUSIONS: The EBV-associated GC-specific humoral response was exclusively directed against lytic cycle immediate-early and early antigens, unlike other EBV-associated malignancies such as nasopharyngeal carcinoma and lymphoma where humoral response is primarily directed against late lytic antigens. Specific anti-EBV antibodies could have utility for clinical diagnosis, epidemiologic studies, and immune-based precision treatment of EBV-positive GC.
Databáze: OpenAIRE
Externí odkaz: